The fruit bargain: market access for know-how

From the treaty's tariff schedule (Annex 2A) and the signed text:

The plans themselves are five-year programmes agreed under a Memorandum of Cooperation signed on 17 March 2025 — the day after negotiations were launched. The treaty (Annex 14A.3) sets out their "broad pillars". For kiwifruit: Centres of Excellence under India's horticulture mission, "enhancing availability of quality planting materials", grower training, and post-harvest and supply-chain help. For apples: joint R&D with Indian growers on pests, climate resilience and productivity; packhouse, cold-chain and processing assistance; a long-term aim of high-density apple Centres of Excellence; and — most debated — this:

Two details matter and are often skipped. First, the variety-exchange language in the general horticulture article is caveated: exchange of high-yield varieties and planting materials happens "subject to agreement and after completion of all related formalities … all subject to relevant intellectual property protection in India and in New Zealand" (Annex 14A.3(2)(c)). Nothing in the treaty hands over germplasm unconditionally. Second, the IP pillar quoted above is framed as building India's plant-variety-rights regime so that protected varieties can be commercially introduced — the same licensed model NZ uses elsewhere — not as a waiver of protection. Critics respond that the direction of travel is nonetheless fixed by treaty, while the adequacy of India's protection is not.

This is where the "taxpayer-funded" question lands, and the honest answer is: partly, with industry money alongside — and the mix differs between apples and kiwifruit.

• The breeding science is substantially Crown. New Zealand's premium apple and kiwifruit varieties were bred at Plant & Food Research, a 100% Crown-owned research institute (since 1 July 2025, folded into the New Zealand Institute for Bioeconomy Science, still Crown-owned). Its revenue has long been a mix of public science funding and commercial contracts — so decades of public investment sit underneath the cultivar portfolio, alongside industry co-investment.
• Apples: commercialisation runs through Prevar Ltd, a joint venture between NZ Apples & Pears (the grower body), Plant & Food Research (the Crown), and Apple and Pear Australia (16%). Prevar holds exclusive access to the Crown institute's apple and pear genetic repository and licenses varieties (Dazzle, Rockit, Sassy and others; older PFR-bred varieties include Jazz, Envy and Pacific Rose) to growers in NZ and overseas. Royalties flow back to those shareholders — meaning both growers and the Crown share licensing income.
• Kiwifruit: varieties like SunGold came from the Plant & Food breeding programme co-funded by Zespri — which is grower-owned, not government-owned. Since 2021 breeding sits in the Kiwifruit Breeding Centre, a 50/50 joint venture between Zespri and the Crown institute. Zespri commercialises the varieties and pays for the privilege; licensed offshore growing (Italy, France, Japan, South Korea and elsewhere) is already core to its 12-month supply model.

So the argument some growers make — public science was funded to benefit New Zealand growers, not to build up offshore competitors — starts from an accurate premise about who paid. The counter-argument is also grounded in fact: licensing NZ-bred varieties offshore, with royalties returning to the Crown and to growers, has been the sector's deliberate business model for two decades. The genuine difference with the FTA is control: existing offshore plantings are licensed to growers who supply NZ-controlled marketers, whereas the action plans assist India's own domestic industry — one New Zealand doesn't control — and do so as a treaty obligation with market access riding on delivery.

Contrary to a common assumption on both sides, the action plans are expected to be largely industry-funded, not general-taxpayer-funded. NZ Apples & Pears has said it is responsible for funding the apple sector's cooperation programme, and has flagged possible "user pays" charges on exporters who use the India quota. The enabling bill's Part 4 creates the quota administration systems and allows levies — collected from the industry — to fund the cooperation activities. It also shields the Crown from liability for Indian suspension decisions.

That reframes the fiscal question. The taxpayer's historical contribution is embedded in the breeding programmes; the ongoing cost of the plans falls mainly on growers and exporters — the same people who stand to earn the quota returns, and the same people some of whom worry the plans will eventually compete with them. Whether that trade is worth it is exactly what growers will weigh differently depending on their time horizon and exposure to India.

This is the crux of the risk argument, and it has real texture on both sides.

India's regime is different by design. India is not a member of UPOV, the international plant-variety-rights convention that underpins protection in NZ's other markets. Its Protection of Plant Varieties and Farmers' Rights Act 2001 does register and protect varieties — but it also famously guarantees farmers the right to save, use, re-sow, exchange and (unbranded) sell the produce and seed of protected varieties. Enforcement institutions are still maturing. The Apple Action Plan's IP pillar exists precisely because of this gap: supporters read it as "fix the fence before the stock goes in"; critics read it as the stock being committed before the fence exists.

New Zealand has lived the downside case once already. In the late 2010s Zespri discovered its protected SunGold variety had been taken to China without authorisation and propagated at scale — by its estimates at least 4,000 hectares, approaching half of NZ's licensed plantings at the time. Zespri sued the NZ-based grower responsible and won: the High Court awarded roughly $12–15 million in damages in 2020–21. Collecting proved another matter — the defendant's company held almost no assets, and Zespri had to petition Chinese courts to recognise the NZ judgment while the unlicensed area kept growing. The episode is the factual backbone of the critics' warning that once planting material crosses a border, legal victories don't necessarily restore control.

The counterpoint is that the comparison is imperfect. The China plantings were theft, outside any framework; the FTA route is a negotiated, government-to-government arrangement in which any variety transfer is explicitly "subject to agreement" and "subject to relevant intellectual property protection", with industry bodies — who own the commercial rights and carry the scar tissue from China — at the table deciding what, if anything, is licensed. Prevar and Zespri are under no treaty obligation to license any specific cultivar; the obligation on New Zealand is to run the cooperation programmes. Which cultivars, on what terms, remains a commercial decision.